On 10 August 2022 PolyNovo Limited announced that the first patient had been enrolled in its Randomized Controlled Trial (RCT) evaluating the clinical safety and efficacy of NovoSorb® SynPath for the treatment of chronic diabetic foot ulcers (DFU's). Chronic wounds advance quickly and, if not treated appropriately may necessitate amputation. SynPath is designed to promote healing by providing a porous network of biodegradable synthetic polymers which act as a template to support the proliferation of vital cells involved in tissue regeneration.

Currently 25 subjects have been enrolled in the trial out of a target 138. A review of the first 25 patients is being completed to confirm the study protocol, and The company anticipates making an amendment. Diabetic foot ulcers affect more than 300,000 Americans annually and accounts for more than USD 9 billion in annual expenditures.